XERIS BIOPHARMA HOLDINGS, INC. — Revenue by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/93638ea3-61b3-4d6e-8537-df20943bd86d/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $291.8M | 2025-01-01 – 2025-12-31 | evidence 0001867096-26-000016 |
| FY 2024 | $203.1M | 2024-01-01 – 2024-12-31 | evidence 0001867096-25-000039 |
| FY 2023 | $163.9M | 2023-01-01 – 2023-12-31 | evidence 0001867096-24-000031 |
| FY 2022 | $110.2M | 2022-01-01 – 2022-12-31 | evidence 0001867096-23-000031 |
| FY 2021 | $49.6M | 2021-01-01 – 2021-12-31 | evidence 0001867096-23-000031 |
| FY 2020 | $20.2M | 2020-01-01 – 2020-12-31 | evidence 0001867096-22-000040 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
XERIS BIOPHARMA HOLDINGS, INC. — all facts · Net Income · Operating Income